"We saw an unfortunate and pretty dramatic [market] correction over the last several months in small oncology biotechs."
– Ron Squarer, CEO of Array BioPharma Inc.

"Given solid efficacy, acceptable tolerability, and the dearth of treatment options, our conviction that Abraxane plus gemcitabine will become the new standard of care in pancreatic cancer is high."
– Eric Schmidt, Cowen & Co. analyst

"One can now reasonably conclude that Gilead Sciences Inc. has a safe, once-per-day pill that can cure [over] 90 percent of naïve genotype 1 Hep C patients."
– Mark Schoenebaum, Biotech & Pharmaceuticals Analyst, ISI Group